1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioNTech SE

BioNTech SE

BNTX
BioNTech SEUS flagNASDAQ Global Select
99.26
USD
+0.80
- -
24.93BMarket Cap

Total Valuation

BioNTech SE carries a market capitalization of 24.93B, placing it among publicly traded companies globally. Its enterprise value stands at 6.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap24.93B
Enterprise Value6.00B

Share Statistics

BioNTech SE currently has 251.20M shares outstanding.

Shares Outstanding251.20M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 7.61, and the price-to-book ratio stands at 1.15.

PE RatioN/A
PS Ratio7.61
PB Ratio1.15
P/TBV Ratio1.28
P/FCF Ratio22.03
P/OCF Ratio29.65

Enterprise Valuation

On an enterprise value basis, BioNTech SE trades at an EV/EBITDA multiple of 6.61 and an EV/FCF ratio of 6.50. The EV/Sales ratio of 2.26 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.53 provides insight into valuation relative to core operating earnings.

EV / Sales2.26
EV / EBITDA6.61
EV / EBIT11.53
EV / FCF6.50

Financial Position

BioNTech SE maintains a current ratio of 7.85, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.78, indicating elevated leverage, while an interest coverage ratio of -74.68 demonstrates limited ability to service its debt obligations.

Current Ratio7.85
Quick Ratio7.71
Debt / Equity1.78
Debt / EBITDA-0.56
Interest Coverage-74.68

Financial Efficiency

Return on Equity (ROE)-9.30
Return on Assets (ROA)-8.03
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)-1.89
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.92

Taxes

Over the trailing twelve months, BioNTech SE has paid 56.90M in income taxes, reflecting an effective tax rate of 216.19.

Income Tax56.90M
Effective Tax Rate216.19

Stock Price Statistics

BioNTech SE's stock has declined approximately -0.49122807% over the past 52 weeks. The 50-day moving average sits at 97.64, while the 200-day moving average is 97.61.

Beta (5Y)N/A
52-Week Price Change-0.49122807%
50-Day Moving Average97.64
200-Day Moving Average97.61
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, BioNTech SE generated 2.65B in revenue and converted that into -1.69B in net income, yielding earnings per share of -6.82. EBITDA reached -560.10M, while operating income came in at -1.24B.

Revenue2.65B
Gross Profit2.00B
Operating Income-1.24B
Pretax Income-1.63B
Net Income-1.69B
EBITDA-560.10M
EBIT-1.24B
Earnings Per Share (EPS)-6.82

Balance Sheet

BioNTech SE holds 14.78B in cash and equivalents against 316.10M in total debt, resulting in a net debt position of -9.42B. Total book value stands at 17.76B, with working capital of 13.35B providing operational flexibility.

Cash & Cash Equivalents14.78B
Total Debt316.10M
Net Debt-9.42B
Equity (Book Value)17.76B
Book Value Per Share70.69
Working Capital13.35B

Cash Flow

BioNTech SE produced 679.70M in operating cash flow over the past twelve months. After subtracting -235.00M in capital expenditures, free cash flow totaled 444.70M - equivalent to 1.80 per share.

Operating Cash Flow679.70M
Capital Expenditures-235.00M
Free Cash Flow444.70M
FCF Per Share1.80

Margins

BioNTech SE operates with a gross margin of 75.47, reflecting its pricing power and cost economics. The operating margin of -46.66 and net profit margin of -63.64 provide insight into operational efficiency.

Gross Margin75.47
Operating Margin-46.66
Pretax Margin-61.49
Profit Margin-63.64
EBITDA Margin-21.14

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.53
FCF Yield4.54

Scores

BioNTech SE posts an Altman Z-Score of 6.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.79